Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DNDI-0690 in Healthy Subjects
NCT03929016Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNDI-0690 in visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL) (11 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoints: Treatment-emergent adverse events, Changes in 12-lead electrocardiogram parameters and 3 more. Started Apr 2019; status: completed.
02
Drugs
DNDI-0690
03
Conditions
visceral leishmaniasis (VL)cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT03929016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929016.